Development and Characterization of Pseudotype-based Microneutralization Assay to Assess Functionality of Anti-rabies Protein G Antibodies
F1000Research · 06.10.2026 · 15 · 718
DOI: 10.12688/f1000research.178284.2 ↗Kurz gefasst
Fachartikel in der Zeitschrift F1000Research, online erschienen am 06.10.2026. Verfasst von Antonelli R und 10 weiteren Autor:innen. Beteiligte Einrichtung: Vismederi, siena, 53100, Italy. Hauptthemen laut MEDLINE: Rabies virus, Neutralization Tests, Rabies Vaccines, Antibodies, Neutralizing. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This research was funded by GlaxoSmithKline Biologicals SA.
Abstract (Originalsprache)
Background
Rabies virus (RABV) is a neurotropic zoonotic pathogen responsible for an estimated 60,000 human deaths annually. Despite widespread vaccination programs, rabies remains a substantial public health burden, particularly in regions with limited access to post-exposure prophylaxis (PEP). Standard serological assays for evaluating rabies vaccine immunogenicity, including the Rapid Fluorescent Focus Inhibition Test (RFFIT) and the Fluorescent Antibody Virus Neutralization (FAVN) test, require live virus handling under biosafety level 3 (BSL-3) conditions, limiting their scalability and broader implementation.
Methods
We developed and characterized a pseudotype-based microneutralization assay using a lentiviral HIV-1 backbone to generate pseudotyped viral particles expressing glycoproteins from three antigenically distinct rabies virus strains: CTN-1 V5, CVS-11, and Pasteur. Neutralization assays were performed under BSL-2 conditions, and assay performance was evaluated in terms of sensitivity, specificity, and suitability for high-throughput applications.
Results
The pseudotype-based assay enabled sensitive and reproducible detection of rabies virus–neutralizing antibodies across the three glycoprotein variants. The platform demonstrated robust performance under BSL-2 containment, supporting efficient and scalable testing. Inclusion of antigenically distinct strains broadened detection capacity and improved the assessment of strain-specific neutralizing responses.
Conclusions
This pseudotype-based microneutralization assay represents a safe, flexible, and scalable alternative to conventional live-virus neutralization tests. By enabling high-throughput rabies serology under BSL-2 conditions, this platform supports vaccine evaluation and seroepidemiological surveillance, particularly in settings where BSL-3 infrastructure is limited.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Vismederi, siena, 53100, Italy.
- GVGH, GSK Vaccines Institute for Global Health, Siena, Italy.
- Department of Public Health, Experimental and Forensic Medicine, University of Pavia, Pavia, 27100, Italy.
- Department of Molecular and Developmental Medicine, University of Siena, Siena, 53100, Italy.
ORCID-Profile: Vezzani G, Guerrini N, Dapporto F, Molesti E
Förderung
- This research was funded by GlaxoSmithKline Biologicals SA
Zitieren
APA
R, A., G, V., N, G., V, G., F, D., M, I., R, L., E, M., O, R., E, M., & A, M. (2026). Development and Characterization of Pseudotype-based Microneutralization Assay to Assess Functionality of Anti-rabies Protein G Antibodies. F1000Research, 15, 718. https://doi.org/10.12688/f1000research.178284.2
Vancouver
R A, G V, N G, V G, F D, M I, et al. Development and Characterization of Pseudotype-based Microneutralization Assay to Assess Functionality of Anti-rabies Protein G Antibodies. F1000Research. 2026;15:718. doi:10.12688/f1000research.178284.2
BibTeX
@article{R2026,
author = {R, Antonelli and G, Vezzani and N, Guerrini and V, Giovagnoli and F, Dapporto and M, Iturriza and R, Loomis and E, Montomoli and O, Rossi and E, Molesti and A, Manenti},
title = {Development and Characterization of Pseudotype-based Microneutralization Assay to Assess Functionality of Anti-rabies Protein G Antibodies},
journal = {F1000Research},
year = {2026},
volume = {15},
pages = {718},
doi = {10.12688/f1000research.178284.2}
}
EUVIMED